Key result
The Optimizer Smart System delivering cardiac contractility modulation is considered safe and feasible for heart failure patients not qualifying for CRT, pending further large randomized trials.
Why the study?
Heart failure mortality remains high despite progress in treatment, prompting review of cardiac contractility modulation delivered by the Optimizer Smart System for patients who do not qualify for CRT.
Does the Optimizer Smart System (cardiac contractility modulation) improve outcomes safely in patients with heart failure who do not qualify for CRT?
Does the Optimizer Smart System (cardiac contractility modulation) improve outcomes safely in patients with heart failure who do not qualify for CRT?
The Optimizer Smart System offers a safe and feasible device therapy option (cardiac contractility modulation) for heart failure patients ineligible for CRT, though more robust RCT data is needed.
Answers are grounded in this paper and cite their sources.
Extends safety data for cardiac contractility modulation in CRT-ineligible HF; leaves open efficacy until large RCTs report.
Introduction: Heart failure (HF) is a major cause of morbidity and mortality throughout the world. Despite the significant progress in the prevention and treatment of HF, mortality rates still remain high. Device therapy for HF includes cardiac resynchronization therapy (CRT) and the use of an implantable cardioverter-defibrillator (ICD). Recently, a new device therapy for the treatment of HF became available, called cardiac contractility modulation (CCM). CCM is a new device therapy for patients with HF who do not qualify for CRT. It is implanted in a minimally invasive manner to improve the patient’s morbidity. Optimizer Smart System is a new device that delivers CCM therapy.Areas covered: We review the function of the Optimizer Smart System, the data from the recent clinical trials, and discuss its efficacy and future projections in the treatment for HF.Expert opinion: CCM therapy provided with the Optimizer® Smart System is safe, feasible, and applicable to a wide range of patients with HF. To demonstrate the effectiveness of the Optimizer Smart System’s use merits further large multicenter randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Chera et al. (2021) conducted a review in chronic heart failure. Optimizer Smart System (cardiac contractility modulation) was evaluated. The Optimizer Smart System delivering cardiac contractility modulation is considered safe and feasible for heart failure patients not qualifying for CRT, pending further large randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: